Score breakdown · Provider-Selection Integrity rubric
| Criterion | Awarded | Max | Rationale |
|---|---|---|---|
| Payment & affiliate disclosure | 2 | 25 | -23. No payment or affiliate disclosure on the ranking page or anywhere else on the site. No identification of commercial partners. No paid-vs-editorial distinction. No labeling of press-release-distributed content as such. |
| Provider-selection methodology | 3 | 20 | -17. No published rubric. Criteria mentioned narratively only. The ranking is a single provider named “Best of 2026” with no methodology that could generate that ranking. Reproducibility test fails completely. |
| Author E-E-A-T | 3 | 20 | -17. No named authors. “Editor’s Choice” designation appears on the site; no editor is named. No bios. No credentials. No bylines. |
| Provider verification rigor | 2 | 15 | -13. No pharmacy verification of the named provider. No state board citation. No licensure verification. Clinical-staff claims about the recommended provider are restated from provider marketing without independent check. |
| Pricing transparency | 1 | 10 | -9. No pricing verification. Provider marketing prices are restated without real-cart audit. No dose-structure distinction. |
| Update cadence & corrections | 1 | 10 | -9. No verifiable per-page dates. No corrections log. No version history. The site presents as static. |
| Total | 12 | 100 |
Editorial findings — strengths
- The site exists and is reachable. There are no other strengths identifiable under the published rubric.
Editorial findings — weaknesses
- Names a single provider as “Best of 2026” with no published methodology that could generate that ranking.
- Uses an “Editor’s Choice” designation without naming an editor anywhere on the site.
- No payment or affiliate disclosure of any kind.
- No pharmacy verification, no licensure verification, no clinical-staff verification of the recommended provider.
- Distribution pattern — identical or near-identical phrasing across multiple unaffiliated-looking domains — is consistent with paid press-release placement.
Adjudication note
One-point discrepancy across the matrix. Below threshold. No adjudication. Final: 12/100. Signed off May 20, 2026.
Investigation flag
This site is one of the five domains that named the same single GLP-1 telehealth provider (CoreAge Rx) as “Best of 2026” between January and April 2026, using language that is materially similar across unaffiliated-looking domains. The pattern is documented in the home-page investigation block and in the full methodology paper. In the audit's framework, this pattern is the most reliable single indicator of press-release-distributed paid placement.
Right of reply
Site contacted at WHOIS-registered email address on May 18, 2026 and explicitly asked to confirm or deny whether the ranking was a paid placement. No response received as of publication. Late responses will be appended to this review page and noted in the public corrections log.
Score-challenge protocol: /editorial-standards.html#right-of-reply · Methodology: /methodology.html · ← All reviews